LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

Owen Mumford Pharmaceutical Services

With more than 60 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence spans from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany and France.

Owen Mumford Pharmaceutical Services specialises in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe.

Our offering includes single and multi-dose reusable and disposable auto-injectors, pens and syringes for subcutaneous and intramuscular administration. These innovative products are designed to meet the needs of both our pharmaceutical partners and their patients through simplicity, ease of use and improved safety and patient compliance.

With an established history of developing world-leading custom devices, we have now extended our capabilities to produce platform products. We pride ourselves on our expertise, support and personal offering; designing products with patient needs at the forefront of mind and to simplify our partners combination product development process. Therefore, reducing complexity and risk for the pharmaceutical and biotech industry.

Our products are supported by our services, and we work with our partners every step of the way, supporting and guiding from initial concept stage through to taking the solution to market.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025